Sezary cells, the malignant T cells in mycosis fun
Mycosis fungoides is the most common of primary cutaneous lymphomas (1) (2) (3) . Early mycosis fungoides skin lesions present as erythematous patches that may progress to raised plaques or tumors (2, 4) . As shown in Figure 1 , mycosis fungoides tumor cells, or Sezary cells, are epidermotropic, small to medium-sized lymphocytes that are typically CD4 ϩ and CD7 Ϫ (4 -6). Although early (patch stage) mycosis fungoides often follows an indolent course, approximately one quarter of patients with generalized disease progress to a more advanced clinical stage, and Ն20% of these patients eventually die of the disease (7, 8) . Mycosis fungoides may also undergo transformation to cutaneous large T-cell lymphoma or present in a leukemic form termed Sezary syndrome, both of which have a grave prognosis (5, 7) . Because a significant proportion of patients with mycosis fungoides undergo clinical progression associated with a high mortality, it may be important to initiate treatment early in the course of the disease.
Chemotherapeutic and radiation-based treatments have been moderately effective in early cases of mycosis fungoides; however, the disease often recurs, and these treatment approaches have limited efficacy in more advanced stages or systemic disease (9, 10) . Resistance to multiple chemotherapeutic agents has been attributed to a decreased sensitivity of Sezary cells to apoptosis (10 -12) . Sezary cells have been directly shown to be resistant to exogenous apoptotic agents such as dexametha-sone and retinoic acid when cultured in the presence of interleukin-15, a cytokine produced by both Sezary cells and keratinocytes (13) . Furthermore, the number of apoptotic tumor cells within mycosis fungoides lesions is reduced in advanced disease compared with in early disease (14) , suggesting that Sezary cells also develop increased resistance to endogenous inducers of apoptosis with disease progression.
Physiologic triggers of apoptosis in the skin include the galectins, a family of mammalian lectins or carbohydrate-binding proteins that bind to cell surface glycoproteins or glycolipids and regulate cell growth, cell adhesion, and cell death (see [15] [16] [17] [18] for review). Different galectins can be either pro-or anti-apoptotic (19 -30) . Galectin-1 induces Fasindependent death of T cells, as well as prostate and breast cancer cells (19 -24) . Galectin-7 is also pro-apoptotic (25) , and galectin-7 overexpression has been implicated in apoptosis of sun-damaged keratinocytes (26) . Several galectins, including galectins 1 and 7, have been identified in skin (26, FIGURE 1. Glycophenotype of mycosis fungoides lesions. A, representative patch stage mycosis fungoides lesion with Sezary cells (arrows in all panels) infiltrating epidermis and dermis (H&E stain; for all panels, 400ϫ; inset, 1000ϫ). B, expression of galectin-1 in mycosis fungoides lesions. Galectin-1 immunoreactivity is visible in the dermis, and galectin-1 ϩ cells are infiltrating the epidermis. Cytoplasmic immunoreactivity of Sezary cell within the epidermis (inset ) demonstrates abundant expression of galectin-1. C, CD3 immunostaining demonstrates numerous Sezary cells infiltrating the epidermis. D-F show glycosylation patterns visualized by lectin histochemistry. D, PHA reacts with branched N-glycans. Sezary cells are strongly PHA ϩ , as are surrounding keratinocytes. E, SNA reacts with terminal sialic acid residues in ␣2,6 linkage, primarily on N-glycans. Absent SNA reactivity of Sezary cells contrasts with strong SNA reactivity of keratinocytes. F, PNA reacts with non-sialylated O-glycans. Absent PNA reactivity of Sezary cells contrasts with strong PNA reactivity of keratinocytes. [31] [32] [33] [34] [35] , implying that Sezary cells may acquire resistance to endogenous pro-apoptotic galectins.
Sezary cells are typically CD7 Ϫ . CD7 is a T-cell surface glycoprotein that binds galectin-1 and is essential for galectin-1-mediated T-cell death (36, 37) . In addition to the CD7 polypeptide, galectin-1-mediated T-cell apoptosis requires the expression of specific saccharide ligands that are present on a subset of glycoprotein receptors, including CD7 (36) . A recent report examined a panel of Sezary cell lines and correlated lack of CD7 expression with resistance to galectin-1-induced apoptosis (38) . However, tumor cells are known to have aberrant patterns of cell surface glycosylation, a feature that contributes to the malignant phenotype (39) . This suggests that absence of CD7 on Sezary cells and altered cell surface glycosylation could both confer resistance to galectin-1-mediated apoptosis. In the present study, we characterized the expression pattern of saccharides and glycoprotein receptors recognized by galectin-1 on Sezary cells in primary mycosis fungoides skin lesions and on established Sezary cell lines. Using Sezary cell lines, we examined the relationship between CD7 expression, cell surface glycosylation, and susceptibility to galectin-1 death.
MATERIALS AND METHODS

Reagents
The Hut78, HH, and CEM cell lines were obtained from the American Type Culture Collection (Gaithersburg, MD). The MyLa 2059 (mycosis fungoides) and SeAx (Sezary syndrome) cell lines were the kind gift of Dr. Keld Kaltof, University of Aarhus, Denmark, as previously described (13) . The SeAx/i designation refers to the SeAx cells grown in the absence of exogenous interleukins added to the culture, as described in (13) . Cell cultures were maintained in RPMI 1640 medium (Life Technologies, Gaithersburg, MD), with 10% fetal bovine serum and 10 mM HEPES (complete media). Human recombinant galectin-1 was prepared as described previously (20) and was used for preparation of a rabbit polyclonal galectin-1 antiserum. Lectins, antibodies, and other reagents used in the study were as follows: Sambucus nigra agglutinin (SNA) 
Mycosis Fungoides Biopsy Selection
Archival tissue from 15 mycosis fungoides biopsy specimens from the Surgical Pathology Division of the Department of Pathology and Laboratory Medicine at UCLA were examined, including 6 patchstage, 6 plaque-stage, and 3 tumor-stage lesions. All cases were documented as CD4 ϩ and CD7 Ϫ by immunohistochemistry at the time of diagnosis.
Immunohistochemistry and Lectin Staining
Three-to five-micrometer sections of formalinfixed skin biopsies were stained as previously described (40, 41), using primary antiserum or lectins at the following dilutions: rabbit antigalectin-1 (1/1000); biotinylated-PHA (1/100); biotinylated-PNA (1/40); and biotinylated-SNA (1/40). To detect bound antibody or lectins, slides were incubated with goat anti-rabbit Ig-HRP (1/ 1000) or streptavidin-HRP (1/200) for 30 minutes or 2 hours, respectively, at room temperature. After washing, slides were developed with AEC.
Phenotypic Analysis
Either with 0.2 g of the indicated antibody or with 0.5 g of biotinylated lectin in a final volume of 100 L, 10 5 cells of the indicated cell lines were incubated for 45 minutes at 4°C, followed by FITCconjugated secondary antibody or FITC-conjugated streptavidin, respectively, for 45 minutes at 4°C. Controls were equivalent amounts of IgG1 or IgG2a for the relevant antibodies, or 0.5 g of biotinylated BSA for the lectins. Flow cytometry data was acquired and analyzed using Becton Dickinson FACScan and CELLQuest software. For analysis after neuraminidase treatment, cells were first incubated with 25 mU of V. cholerae neuraminidase in Hanks balanced salt solution, or in buffer alone, for 2 hrs at 37°C, then washed and analyzed as above.
Cell Death Assays
Galectin-1 death assays were performed essentially as previously described (20, 42) . Briefly, 10 5 cells of the indicated cell lines were incubated with 20 M of galectin-1 in 200 L of media containing 1.0 mM dithiothreitol (DTT), or in media with DTT alone as control, for 6 hours at 37°C in 5% CO 2 . Cells were analyzed on a Becton Dickinson FACScan. Cell death was assessed by annexin V binding and propidium iodide permeability, using CELLQuest software. Percentage cell death was determined as follows: 100
. Statistical analysis was done by analysis of variance, and posthoc analysis, by the Newman-Keuls multiple comparison test using Prism 3.0 software by Graphpad.
Immunoblotting
Immunoblotting for galectin-1 expression by the indicated cell lines was performed with rabbit antihuman galectin-1 polyclonal antiserum (1:10,000). Purified recombinant galectin-1 and the -35 thymic stromal cell line (gift of Dr. Ken Dorshkind, UCLA School of Medicine) were used as positive controls. Bound antibody was detected with goat anti-rabbit IgG-HRP (1:5000). Immunoblots were developed for 1 minute by the Enhanced ChemiLuminescence method according to the manufacturer's directions and immediately were exposed for 30 seconds to 1 minute.
RESULTS
Galectin-1 Immunoreactivity in Mycosis Fungoides Biopsies
We examined galectin-1 expression in 15 mycosis fungoides skin lesions. In all cases of patch and tumor stage lesions, galectin-1 was present within both dermis and epidermis in close proximity to infiltrating lymphocytes and Sezary cells (Fig. 1B) . There was strong galectin-1 reactivity on the surface of infiltrating Sezary cells and lymphocytes in the epidermis and dermis, compared with the background of predominantly negative keratinocytes. In addition, the galectin-1 immunoreactivity in the cytoplasm of some Sezary cells (inset, Fig. 1B ) suggested that the tumor cells synthesized galectin-1, as well as being exposed to abundant galectin-1 in the extracellular milieu. In the dermis, there were also scattered galectin-1 ϩ non-neoplastic cells, including fibroblasts, endothelial cells, and macrophages, as previously described (34, 35) .
Glycosylation Patterns in Mycosis Fungoides Lesions
Galectin-1 binds to specific saccharide ligands on T-cell glycoproteins to trigger cell death (37) . These saccharide structures can be detected by reactivity with specific plant lectins (41) (42) (43) (44) (45) . As susceptibility to galectin-1 is regulated by expression of these saccharide ligands, it was important to characterize the saccharide structures on Sezary cells.
Galectin-1 preferentially binds poly-N-acetyllactosamine (poly-LacNAc)-containing saccharides on T-cell surface glycoproteins (42) . Poly-LacNAc sequences can be found on branched N-glycans that also bind the plant lectin phytohemagglutinin (PHA; 42, 46) . To determine whether Sezary cells expressed poly-LacNAc sequences, we examined the cells for reactivity with PHA. In all samples, strong PHA reactivity was seen on the surface of both Sezary cells and small, round lymphocytes within the dermis and epidermis (Fig. 1D) . This was consistent with prior reports of Sezary cells bearing the branched N-glycans recognized by PHA (47, 48) . Strong PHA reactivity was also seen on other cells within the dermis and epidermis.
The plant lectin PNA detects unsialylated core 1 O-glycans on cell surface glycoproteins. Sialylation of O-glycans by the ST3Gal I enzyme blocks PNA binding and also prevents the addition of polyLacNAc sequences to form core 2 O-glycans that bind galectin-1 and are required for galectin-1-induced T-cell death (41, 42, 49) . For non-neoplastic human thymocytes and T cells, the ability to bind PNA correlates with susceptibility to galectin-1-induced death (20, 21) . In all samples, there was no detectable staining of Sezary cells with PNA (Fig.  1F) . The PNA Ϫ Sezary cells contrast with the PNA ϩ keratinocytes and with scattered small PNAϩ lymphocytes observed within the dermis and epidermis. The small PNA ϩ lymphocytes in the dermis were concentrated in perivascular areas (data not shown) and are likely reactive, non-neoplastic lymphocytes that bind high levels of PNA (50) .
The plant lectin Sambucus nigra agglutinin (SNA) detects ␣-2,6-linked sialic acid residues on cell surface glycoproteins (45) . The presence of a terminal ␣-2,6-linked sialic acid can mask the LacNAc sequences that are preferred galectin-1 ligands (37, 51) , and SNA reactivity of medullary thymocytes and T-cell lines correlates with loss of susceptibility to galectin-1 (43, 45) . In all samples, no SNA reactivity was detected on infiltrating Sezary cells or on small round lymphocytes present in the dermis and epidermis (Fig. 1E) . The SNA Ϫ Sezary cells contrasted with strongly SNA ϩ maturing epidermal keratinocytes.
In summary, lectin histochemistry of Sezary cells in mycosis fungoides lesions demonstrated that the malignant cells were PHA ϩ and SNA Ϫ . Although this glycophenotype correlates with the phenotype of nonneoplastic T cells that are susceptible to galectin-1, the Sezary cells in the lesions were also PNA Ϫ , indicating that the Sezary cells bear core 1 O-glycans capped with sialic acid. The presence of sialylated core 1 O-glycans on Sezary cells would reduce susceptibility of these cells to death triggered by galectin-1 present in skin (42, 49) .
Cell Surface Phenotype of Sezary Cell Lines
The abundant galectin-1 immunoreactivity that we observed in mycosis fungoides biopsies (Fig. 1B) indicates that Sezary cells are exposed to galectin-1 in vivo. We hypothesized that Sezary cells may resist galectin-1-mediated apoptosis either because the malignant cells do not express CD7 that is essential for galectin-1-mediated apoptosis (36) or because PNA Ϫ Sezary cells have aberrant cell surface glycosylation that contributes to decreased galectin-1 sensitivity. To examine the relationship between CD7 expression, cell surface glycosylation, and susceptibility to galectin-1, we analyzed cell surface glycosylation and CD7 expression of four Sezary cell lines, Hut78, MyLa 2059, HH, and SeAx/i. As a control, we analyzed a subclone of the CEM T-lymphoblastoid cell line that we have previously demonstrated is highly susceptible to galectin-1 (37) . As shown in Figure 2 , CD7 surface expression differed significantly among the five cell lines. HH and SeAx/i cells exhibited high levels of CD7 expression, comparable to that of CEM cells. In contrast, the Hut78 and MyLa 2059 cells were CD7
Ϫ . Hut78 and MyLa 2059 cells also had lower surface levels of CD4 than HH and SeAx/i cells, although we have previously found that CD4 expression is not required for galectin-1 susceptibility (37) . None of the cell lines expressed detectable cell surface CD8.
Despite differences in CD7 expression, the four Sezary cell lines had similar cell surface glycosylation profiles. All four cell lines strongly bound PHA. There was very dim staining of Hut78 and MyLa 2059 with PNA (background mean fluorescence channels 4 and 15, respectively), whereas no binding of PNA over background was observed for HH and SeAx/i cells. There was very dim staining of HH and SeAx/i with SNA (background mean fluorescent channels 3 and 2, respectively), whereas no binding of SNA over background was observed for Hut78 and MyLa 2059 cells. Thus, all four cell lines demonstrated a lectin-binding profile, i.e., PHA ϩ , PNA -/low , and SNA -/low , identical to that observed for Sezary cells in primary mycosis fungoides skin lesions (Fig. 1) , indicating that the four Sezary cell lines are phenotypically similar to primary Sezary cells with regard to cell surface glycosylation. However, in contrast to the minimal to absent PNA reactivity of the four Sezary cell lines, the galectin-1-sensitive CEM T cell line was strongly PNA ϩ , demonstrating the presence of non-sialylated O-glycans on the CEM cells.
Galectin-1-Mediated Apoptosis of Sezary Cell Lines
To examine the role of CD7 in galectin-1-mediated cell death, we determined the susceptibility of the Sezary cell lines to galectin-1. Significantly, all four Sezary cell lines bound galectin-1, as demonstrated by cell agglutination (data not shown), because other galectin-1 receptors, e.g., CD45, are also expressed by these cells. As shown in Figure 3 , the CD7 Ϫ Sezary cell lines Hut78 and MyLa 2059 demonstrated essentially no galectin-1-induced cell death (Ͻ1%). In contrast, we observed a modest but reproducible and statistically significantly higher level of galectin-1 cell death for the CD7 ϩ HH cell line compared with the case of the CD7 Ϫ Hut78 and MyLa 2059 cells (P Ͻ .05). However, CD7 expression alone was not sufficient for galectin-1-induced death, because SeAx/i cells had a significantly lower level of galectin-1-induced cell death than did HH cells (P Ͻ .05), despite similar levels of CD7 expression on the HH and SeAx/i cell lines (Fig. 2) . CEM T cells, which express CD7 at a level comparable to that seen on HH and SeAx/i, were very sensitive to galectin-1-induced death, as previously reported, so the reduced susceptibility of HH cells and the resistance of SeAx/i cells to galectin-1 cannot solely be attributed to insufficient expression of CD7 by the Sezary cell lines. 
Sialylated O-Glycans on Sezary Cells
The absence of PNA reactivity of Sezary cells in skin lesions and of Sezary cell lines suggested that O-glycans on these cells may be masked by terminal sialic acids. Low PNA binding and sialylated core 1 O-glycans are found on naïve and memory T cells that are resistant to galectin-1, but not on activated effector T cells (50) that are susceptible to galectin-1. This is likely due to competition for acceptor substrate between the ST3Gal I sialyltransferase and the core 2 ␤-1,6-N-acetylglycosaminyltransferase (core 2 GnT) enzyme that creates saccharide ligands required for galectin-1 death (42, 49) . To determine whether sialylated core 1 O-glycans were present on the Sezary cells, cells were treated with V. cholerae neuraminidase to remove sialic acid from cell surface glycoproteins. Neuraminidase treatment dramatically increased PNA binding of all four Sezary cell lines, to levels comparable to that for the CEM cell line (Fig. 4) . Although removal of sialic acid by neuraminidase increased PNA binding, this treatment did not increase susceptibility to galectin-1 cell death (data not shown). This was not surprising; de-sialylated cell surface glycoproteins would still lack core 2 O-glycans, as these structures are added to nascent glycoproteins during synthesis in the Golgi. Thus, sialylation of core 1 O-glycans on Sezary cells may inhibit core 2 O-glycan addition to cell surface glycoproteins and contribute to resistance to galectin-1 death.
Synthesis of Galectin-1 by Sezary Cells
As shown in Figure 1B , immunoreactive galectin-1 was detected within the cytoplasm of Sezary cells in primary skin lesions, indicating that tumor cells synthesize galectin-1. We examined the four Sezary cell lines, HH, SeAx/i, Hut78, and MyLa 2059, for galectin-1 expression by immunoblotting (Fig. 5) . Abundant galectin-1 was detected in the CD7 Ϫ cell lines Hut78 and MyLa 2059. However, no galectin-1 was detected in the CD7 ϩ cell lines HH and SeAx/i. Thus, in these four cell lines, there was an inverse correlation between galectin-1 synthesis and CD7 expression, suggesting that Sezary cells that lack CD7 can express galectin-1 and survive.
DISCUSSION
The resistance of Sezary cells to apoptosis presents a major challenge in developing effective therapies for mycosis fungoides (1, 8) . In this study, we examined 15 biopsy samples of mycosis fungoides lesions to determine whether Sezary cells are exposed to galectin-1 in the skin. In skin, galectin-1 may have several functions, including participating in cell-cell and cell-matrix adhesion, in addition to inducing T-cell apoptosis. In all samples, abundant extracellular galectin-1 was seen in close contact with Sezary cells and associated small round lymphocytes in the dermis and epidermis. The pattern of galectin-1 expression in vivo indicates that CD7 Ϫ Sezary cells are exposed to this apoptotic trigger, yet the tumor cells resist galectin-1 cell death.
We have previously demonstrated reversal of galectin-1 resistance in the CD7 Ϫ Sezary cell line Hut78 by expressing CD7 in these cells (36) . This implied that all other components of the galectin-1 death pathway besides CD7 were present in Hut78 cells. The present study further analyzed the role of CD7 in galectin-1 sensitivity using additional Sezary cell lines. The CD7 Ϫ cell lines Hut78 and MyLa 2059 were resistant to galectin-1-induced cell death. Although the CD7 ϩ cell line HH was modestly susceptible to galectin-1-induced cell death, another CD7 ϩ cell line, SeAx/i, was not susceptible to galectin-1. These findings support the hypothesis that the absence of CD7 is one important factor mediating the reduced sensitivity of Sezary cells to apoptosis via galectin-1 (38) . However, additional factors, i.e., changes in cell surface glycosylation, may also contribute to Sezary cell resistance to galectin-1 death.
In additions to CD7 expression, galectin-1-induced cell death requires expression of a specific glycosyltransferase by T cells, the core 2 GnT (42). The core 2 GnT creates core 2 O-glycans that bear poly-LacNAc sequences preferentially recognized by galectin-1. It is noteworthy that the presence of terminal sialic acid on core 1 O-glycans, added by the ST3Gal I sialyltransferase, inhibits the action of the core 2 GnT enzyme (49) . Additional glycosyltransferases, such as the GnT V or the ST6Gal I, also regulate the expression or accessibility of saccharide ligands recognized by galectin-1 (42, 43, 45, 46, 51) . Thus, in addition to CD7 expression, regulated expression of appropriate glycosyltransferases can also influence susceptibility to galectin-1.
In mycosis fungoides biopsies, the Sezary cells were PHA ϩ , SNA Ϫ , and PNA Ϫ (Fig. 1) . This glycosylation phenotype was also observed for the four Sezary cell lines examined. Loss of CD7 expression and aberrant glycosylation, i.e., low PNA binding, could both contribute to decreased galectin-1 sensitivity (39) . Increased PNA reactivity after neuraminidase treatment of the cell lines indicated that the cells bear primarily sialylated core 1 O-glycans and thus lack the core 2 O-glycans required for T-cell susceptibility to galectin-1 (42).
Detection of galectin-1 in macrophages, dendritic cells, and fibroblasts (Fig. 1) is consistent with prior reports (34, 35) and indicates that many cell types may secrete galectin-1 in skin. We also observed galectin-1 immunoreactivity within the cytoplasm of CD7 Ϫ Sezary cells in skin lesions (Fig.  1B) . This correlated with the abundant galectin-1 expression by the CD7 Ϫ cell lines Hut78 and MyLa 2059 (Fig. 5) ; thus, CD7 Ϫ Sezary cells can express galectin-1 while escaping cell death. The inverse relationship between galectin-1 expression and galectin-1 sensitivity is similar to that described for other neoplasms, e.g., prostate cancer (22) .
What selective advantage would loss of sensitivity to galectin-1 apotosis confer to tumor cells? First, resistance to galectin-1-induced cell death may provide Sezary cells with a survival advantage. Second, production of galectin-1 by Sezary cells might also contribute to apoptotic elimination of reactive tumor-infiltrating T cells. A paracrine effect of galectin-1 released by tumor cells on lymphocytes has previously been proposed (52) . Various types of tumors express death ligands, such as Fas, as a mechanism to eradicate tumor-specific T cells (11, (53) (54) (55) . The expression of galectin-1 by CD7
Ϫ Sezary cells in skin lesions and by CD7
Ϫ Sezary cell lines suggests that lack of CD7 expression contributes to both apoptosis resistance and immune evasion by tumor cells. Indeed, lack of CD7 on circulating Sezary cells has been associated with a poor prognosis in patients (56) .
Our results demonstrate that lack of CD7 expression on Sezary cell lines correlates with reduced susceptibility to galectin-1-induced apoptosis, although CD7 expression was not sufficient to make the HH and SeAx/I cells susceptible to galectin-1 cell death. Altered glycosylation, specifically the presence of sialylated core 1 O-glycans, may also contribute to the reduced galectin-1 sensitivity of Sezary cells. Identification of specific glycosyltransferase genes that regulate susceptibility to galectin-1 apoptosis may provide novel therapeutic targets to enhance tumor cell death in mycosis fungoides.
